This product is a central anticholinergic anti-Parkinson's disease drug that selectively blocks the cholinergic nerve pathways in the striatum, but has less effect on the periphery, thus helping to restore the balance of dopamine and acetylcholine in the brain of Parkinson's patients and improve the patients' Parkinson's disease symptoms.

This product is a lipid-regulating drug of the clofibric acid derivative class. Its mechanism of action in lowering blood lipids is not yet fully understood. It may involve peripheral fat decomposition, reduce the liver's uptake of free fatty acids and reduce the formation of triglycerides in the liver, inhibit the synthesis of very low-density lipoprotein apolipoproteins and reduce the production of very low-density lipoproteins. This product reduces blood triglycerides and increases blood high-density lipoprotein concentrations. Although it can slightly reduce blood low-density lipoprotein cholesterol blood concentrations, it may increase low-density lipoprotein in type IV hyperlipoproteinemia. A 5-year placebo-controlled study showed that this product can reduce the occurrence of severe coronary heart disease sudden death and myocardial infarction. Long-term administration of 10 times the human dose to rats increased the incidence of liver malignancies and benign testicular tumors.

Competitive angiotensin converting enzyme inhibitors prevent angiotensin I from converting to angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. They can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, they can reduce pulmonary capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time. They can be secreted through breast milk and can pass through the placenta.

This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from converting into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce pulmonary capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time. This product can be secreted through breast milk and can pass through the placenta.

1. Anticoagulant effect: This product has a mild anticoagulant activity, and its mechanism of action is similar to that of heparin, but its anticoagulant strength is only 1/50 of that of heparin. 2. Hypolipidemic effect: This product can reduce serum triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL), and increase high-density lipoprotein (HPL). 3. Reduce myocardial oxygen consumption, protect myocardium, and resist myocardial ischemic necrosis. 4. Improve blood rheology, accelerate platelet and red blood cell electrophoresis, reduce blood viscosity, and improve microcirculation. 5. Anti-thrombosis and promote fibrinolysis. 6. Can act on the inner wall of the artery, reduce the permeability of the arterial intima and the absorption of cholesterol.

It can calm and hypnotize the heart, and protect the heart rhythm. It contains 17 kinds of amino acids, 10 kinds of trace elements, D-mannitol and metronidazole. It has obvious sedative and hypnotic effect on the central nervous system of animals, and can significantly prolong the sleep time of animals treated with sodium pentobarbital. Intraperitoneal injection of its hot water extract has obvious hypoxia-resistance effect on experimental animals. Its decoction has a certain promoting effect on the phagocytic function of mononuclear phagocytes. It has a protective effect on arrhythmias caused by aconitine.